{"title": "La FDA de EE. UU. autoriza el uso de emergencia de la vacuna adyuvada contra la COVID-19 de Novavax para personas mayores de 18 a\u00f1os", "author": "Novavax; Inc", "url": "https://www.prnewswire.com/news-releases/la-fda-de-ee-uu-autoriza-el-uso-de-emergencia-de-la-vacuna-adyuvada-contra-la-covid-19-de-novavax-para-personas-mayores-de-18-anos-803384458.html", "hostname": "prnewswire.com", "description": "/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una compa\u00f1\u00eda de biotecnolog\u00eda dedicada al desarrollo y la comercializaci\u00f3n de vacunas de pr\u00f3xima generaci\u00f3n para...", "sitename": "PR Newswire", "date": "2022-07-15", "id": null, "license": null, "body": null, "comments": "Share this article", "commentsbody": null, "raw_text": null, "text": "[Novavax, Inc.](/news/novavax%2C-inc./)\n15 Jul, 2022, 07:20 ET\n[]\n- La vacuna de Novavax es la primera vacuna contra la COVID-19 basada en prote\u00ednas autorizada en los EE. UU.\n- Las inmunizaciones con la vacuna adyuvada contra la COVID-19 de Novavax como serie primaria comenzar\u00e1n despu\u00e9s del lanzamiento del producto y una vez que se reciba una recomendaci\u00f3n de pol\u00edtica de los CDC\nGAITHERSBURG, Maryland, 15 de julio de 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq:\n[NVAX](#financial-modal)), una compa\u00f1\u00eda de biotecnolog\u00eda dedicada al desarrollo y la comercializaci\u00f3n de vacunas de pr\u00f3xima generaci\u00f3n para enfermedades infecciosas graves, ha anunciado hoy que la vacuna adyuvada contra la COVID-19 de Novavax (NVX-CoV2373) recibi\u00f3 la autorizaci\u00f3n de uso de emergencia (EUA) de la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA; Food and Drug Administrataion) para proporcionar una serie primaria de dos dosis para la inmunizaci\u00f3n activa a fin de prevenir la enfermedad por coronavirus 2019 (COVID-19) causada por el coronavirus del s\u00edndrome respiratorio agudo severo 2 (SARS-CoV-2) en individuos de 18 a\u00f1os o mayores.\n\"La autorizaci\u00f3n de uso de emergencia de nuestra vacuna contra la COVID-19 de la FDA concedida hoy proporciona a los Estados Unidos acceso a la primera vacuna contra la COVID-19 basada en prote\u00ednas\", afirm\u00f3 Stanley C. Erck, presidente y director ejecutivo de Novavax. \"Esta autorizaci\u00f3n refleja la solidez de los datos de eficacia y seguridad de nuestra vacuna contra la COVID-19, y subraya la necesidad cr\u00edtica de ofrecer otra opci\u00f3n de vacuna a la poblaci\u00f3n estadounidense mientras la pandemia contin\u00faa\".\n\"Los pacientes y los proveedores de los Estados Unidos ahora tienen acceso a una vacuna contra la COVID-19 basada en prote\u00ednas y respaldada por datos que han demostrado su eficacia, seguridad y tolerabilidad\", afirm\u00f3 la doctora Karen Kotloff, profesora de Pediatr\u00eda de la Facultad de Medicina de la Universidad de Maryland, directora asociada de estudios cl\u00ednicos del Centro para el Desarrollo de Vacunas y la Salud Mundial, codirectora de la Red de Prevenci\u00f3n de la COVID-19 para el ensayo PREVENT-19. \"Es de esperar que la oferta de m\u00e1s tecnolog\u00edas y opciones de vacunas en nuestra cartera de vacunaci\u00f3n, incluidas las que se basan en tecnolog\u00edas que se han utilizado con \u00e9xito durante a\u00f1os, ayude a aumentar la tasa de vacunaci\u00f3n en nuestro pa\u00eds\".\nLa Autorizaci\u00f3n de Uso de Emergencia (EUA) de la FDA se bas\u00f3 en los datos del ensayo cl\u00ednico pivotal de fase 3, PREVENT-19, en el que se inscribieron aproximadamente 30.000 participantes de 18 a\u00f1os o m\u00e1s en EE. UU. y M\u00e9xico. En el ensayo, la vacuna adyuvada contra la COVID-19 de Novavax demostr\u00f3 una eficacia del 90,4 % (intervalo de confianza [IC] del 95 %, del 83,8 % al 94,3 %; P<0,001) con un perfil de seguridad tranquilizador. Entre los participantes de 18 a 64 a\u00f1os de edad, las reacciones adversas (RA) solicitadas tras la administraci\u00f3n de cualquier dosis de la vacuna adyuvada contra la COVID-19 de Novavax fueron dolor/sensibilidad en el lugar de la inyecci\u00f3n (82,2 %), fatiga/malestar (62,0 %), dolor muscular (54,1 %), dolor de cabeza (52,9 %), dolor articular (25,4 %), n\u00e1useas/v\u00f3mitos (15,6 %), enrojecimiento del lugar de la inyecci\u00f3n (7,0 %), hinchaz\u00f3n del lugar de la inyecci\u00f3n (6,3 %) y fiebre (6,0 %). En los participantes de 65 a\u00f1os o m\u00e1s, las RA solicitadas tras la administraci\u00f3n de cualquier dosis de la vacuna adyuvada contra la COVID-19 de Novavax fueron dolor/sensibilidad en el lugar de la inyecci\u00f3n (63,4 %), fatiga/malestar (39,2 %), dolor muscular (30,2 %), dolor de cabeza (29,2 %), dolor articular (15,4 %), n\u00e1useas/v\u00f3mitos (7,3 %), hinchaz\u00f3n del lugar de la inyecci\u00f3n (5,3 %), enrojecimiento del lugar de la inyecci\u00f3n (4,8 %) y fiebre (2,0 %).\nLas dosis de la vacuna adyuvada contra la COVID-19 de Novavax fueron enviadas desde el Serum Institute of India Pvt. Ltd., el mayor fabricante de vacunas del mundo por volumen, y ya est\u00e1n en los EE. UU. El siguiente paso para la vacuna es una recomendaci\u00f3n de uso por parte de los Centros de Control y Prevenci\u00f3n de Enfermedades (CDC).\nA principios de esta semana, el Departamento de Salud y Servicios Humanos (HHS) de los Estados Unidos, en colaboraci\u00f3n con el Departamento de Defensa,\n[anunci\u00f3 un acuerdo](https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=2348182560&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D381075886%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-07-11-U-S-Government-Secures-3-2-Million-Doses-of-Novavax-COVID-19-Vaccine%26a%3Dannounced%2Ban%2Bagreement&a=anunci%C3%B3+un+acuerdo) para asegurar una cantidad inicial de 3,2 millones de dosis de la vacuna adyuvada contra la COVID-19 de Novavax. Estas dosis de vacuna se pondr\u00e1n a disposici\u00f3n de los estados, las jurisdicciones, los socios farmac\u00e9uticos federales y los centros de salud calificados a nivel federal de forma gratuita.\nAdem\u00e1s de la Autorizaci\u00f3n de Uso de Emergencia (EUA) de la FDA, la vacuna contra la COVID-19 de Novavax ha recibido la autorizaci\u00f3n condicional para su uso en personas de 18 a\u00f1os o m\u00e1s por parte de m\u00faltiples organismos reguladores de todo el mundo, incluida la\n[ Comisi\u00f3n Europea](https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=2890647676&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D1150756867%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2021-12-20-European-Commission-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine%26a%3DEuropean%2BCommission&a=%C2%A0Comisi%C3%B3n+Europea) (CE), y la lista de emergencia de la [Organizaci\u00f3n Mundial de la Salud](https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=2836457404&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D3532952207%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2021-12-20-World-Health-Organization-Grants-Second-Emergency-Use-Listing-for-Novavax-COVID-19-Vaccine%26a%3DWorld%2BHealth%2BOrganization&a=Organizaci%C3%B3n+Mundial+de+la+Salud) (OMS).\nEste proyecto ha sido apoyado en parte con fondos federales del Departamento de Salud y Servicios Humanos; Oficina del Subsecretario de Preparaci\u00f3n y Respuesta; la Autoridad de Investigaci\u00f3n y Desarrollo Avanzado Biom\u00e9dico (BARDA), a trav\u00e9s de la Oficina Ejecutiva del Programa Conjunto de Defensa Qu\u00edmica, Biol\u00f3gica, Radiol\u00f3gica y Nuclear del Departamento de Defensa (JPEO-CBRND) en virtud del contrato #MCDC2011-001.\nUso de la vacuna adyuvada contra la COVID-19 de Novavax en los EE. UU.\nLa vacuna adyuvada contra la COVID-19 de Novavax no ha sido aprobada ni autorizada por la Administraci\u00f3n de Alimentos y Medicamentos de los EE. UU. (FDA), pero ha sido autorizada para uso de emergencia por dicha organizaci\u00f3n, en virtud de una Autorizaci\u00f3n de Uso de Emergencia (EUA) para proporcionar una serie primaria de dos dosis a personas de 18 a\u00f1os o m\u00e1s para prevenir la enfermedad por coronavirus 2019 (COVID-19).\nEl uso de emergencia de este producto solo se autoriza por la duraci\u00f3n de la declaraci\u00f3n de que existen circunstancias que justifican la autorizaci\u00f3n del uso de emergencia del producto m\u00e9dico en virtud de la Secci\u00f3n 564(b)(1) de la Ley Federal de Alimentos, Medicamentos y Cosm\u00e9ticos a menos que se ponga fin a la declaraci\u00f3n o se revoque la autorizaci\u00f3n antes.\nUso autorizado\nLa vacuna adyuvada contra la COVID-19 de Novavax est\u00e1 autorizada para su uso bajo una Autorizaci\u00f3n de Uso de Emergencia (EUA) para proporcionar una serie primaria de dos dosis para la inmunizaci\u00f3n activa a fin de prevenir la enfermedad por coronavirus 2019 (COVID-19) causada por el s\u00edndrome respiratorio agudo severo coronavirus 2 (SARS-CoV-2) en individuos de 18 a\u00f1os de edad o mayores.\nINFORMACI\u00d3N IMPORTANTE DE SEGURIDAD\nContraindicaciones\nNo administrar la vacuna adyuvada contra la COVID-19 de Novavax a personas con un historial conocido de reacci\u00f3n al\u00e9rgica grave (por ejemplo, anafilaxia) a cualquier componente de la vacuna adyuvada contra la COVID-19 de Novavax.\nAdvertencias y precauciones\nManejo de las reacciones al\u00e9rgicas agudas: En caso de que se produzca una reacci\u00f3n anafil\u00e1ctica aguda tras la administraci\u00f3n de la vacuna adyuvada contra la COVID-19 de Novavax, se debe disponer inmediatamente de un tratamiento m\u00e9dico adecuado para controlar las reacciones al\u00e9rgicas inmediatas. Monitoree a los receptores de la vacuna adyuvada contra la COVID-19 de Novavax para detectar la aparici\u00f3n de reacciones adversas inmediatas de acuerdo con\n[las directrices de los Centros para el Control de Enfermedades (CDC) y su Prevenci\u00f3n](https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=333043435&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D3604531202%26u%3Dhttps%253A%252F%252Fwww.cdc.gov%252Fvaccines%252Fcovid-19%252Fclinical-considerations%252Fmanaging-anaphylaxis.html%26a%3Dthe%2BCenters%2Bfor%2BDisease%2BControl%2B(CDC)%2Band%2BPrevention%2Bguidelines&a=las+directrices+de+los+Centros+para+el+Control+de+Enfermedades+(CDC)+y+su+Prevenci%C3%B3n).\nMiocarditis y Pericarditis: Los datos de los ensayos cl\u00ednicos proporcionan evidencia de un mayor riesgo de miocarditis y pericarditis tras la administraci\u00f3n de la vacuna adyuvada contra la COVID-19 de Novavax (ver informaci\u00f3n completa sobre la prescripci\u00f3n de la Autorizaci\u00f3n de Uso de Emergencia).\nS\u00edncope (desmayo): Puede ocurrir en asociaci\u00f3n con la administraci\u00f3n de vacunas inyectables. Deben establecerse procedimientos para evitar lesiones por desmayo.\nInmunocompetencia alterada: Las personas inmunocomprometidas, incluidas las que reciben terapia inmunosupresora, pueden tener una respuesta inmune disminuida a la vacuna adyuvada contra la COVID-19 de Novavax.\nLimitaciones de la eficacia de la vacuna: Es posible que la vacuna adyuvada contra la COVID-19 de Novavax no pueda proteger a todos los receptores de la vacuna.\nReacciones adversas\nLas reacciones adversas notificadas en los ensayos cl\u00ednicos tras la administraci\u00f3n de la vacuna adyuvada contra la COVID-19 de Novavax incluyen dolor/sensibilidad en el lugar de la inyecci\u00f3n, fatiga/malestar, dolor muscular, dolor de cabeza, dolor en las articulaciones, n\u00e1useas/v\u00f3mitos, enrojecimiento en el lugar de la inyecci\u00f3n, hinchaz\u00f3n en el lugar de la inyecci\u00f3n, fiebre, escalofr\u00edos, prurito en el lugar de la inyecci\u00f3n, reacciones de hipersensibilidad, reacciones relacionadas con linfadenopat\u00eda, miocarditis y pericarditis.\nSe han reportado miocarditis, pericarditis y anafilaxia tras la administraci\u00f3n de la vacuna adyuvada contra la COVID-19 de Novavax fuera de los ensayos cl\u00ednicos.\nOtras reacciones adversas, algunas de las cuales pueden ser graves, pueden manifestarse tras un uso m\u00e1s generalizado de la vacuna adyuvada contra la COVID-19 de Novavax.\nNotificaci\u00f3n de eventos adversos y errores en la administraci\u00f3n de la vacuna\nEl proveedor de vacunas inscrito en el Programa Federal de Vacunaci\u00f3n COVID-19 es responsable de la notificaci\u00f3n obligatoria de lo siguiente al Sistema de Notificaci\u00f3n de Eventos Adversos a las Vacunas (VAERS):\n- errores en la administraci\u00f3n de la vacuna, ya sea que se asocien o no con un evento adverso,\n- eventos adversos graves (independientemente de la atribuci\u00f3n a la vacunaci\u00f3n),\n- casos de S\u00edndrome Inflamatorio Multisist\u00e9mico (SMI), y\n- casos de COVID-19 que resulten en hospitalizaci\u00f3n o muerte.\nComplete y env\u00ede informes a VAERS en l\u00ednea:\n[https://vaers.hhs.gov/reportevent.html](https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=3361234377&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D980972146%26u%3Dhttps%253A%252F%252Fvaers.hhs.gov%252Freportevent.html%26a%3Dhttps%253A%252F%252Fvaers.hhs.gov%252Freportevent.html&a=https%3A%2F%2Fvaers.hhs.gov%2Freportevent.html). Para obtener m\u00e1s asistencia con la presentaci\u00f3n de informes al VAERS, llame al 1-800-822-7967. Los informes deben incluir las palabras \"Vacuna adyuvada contra la COVID-19 de Novavax\" en la secci\u00f3n de descripci\u00f3n del informe.\nEn la medida de lo posible, notifique los eventos adversos a Novavax, Inc. utilizando la siguiente informaci\u00f3n de contacto o proporcionando una copia del formulario VAERS a Novavax, Inc. Sitio web:\n[www.NovavaxMedInfo.com](http://www.NovavaxMedInfo.com), N\u00famero de Fax: 1-888-988-8809, N\u00famero de tel\u00e9fono: 1-844-NOVAVAX (1-844-668-2829).\nHaga clic para ver la\n[Hoja informativa de la vacuna adyuvada contra la COVID-19 de Novavax, para los profesionales sanitarios que administran la vacuna (proveedores de vacunas) y la informaci\u00f3n de prescripci\u00f3n completa de EUA.](https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=3355049426&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D962771267%26u%3Dhttps%253A%252F%252Fwww.fda.gov%252Fmedia%252F159897%252Fdownload%26a%3DNovavax%2BCOVID-19%2BVaccine%252C%2BAdjuvanted%2BFact%2BSheet%2Bfor%2BHealthcare%2BProviders%2BAdministering%2BVaccine%2B(Vaccine%2BProviders)%2Band%2BEUA%2BFull%2BPrescribing%2BInformation.&a=Hoja+informativa+de+la+vacuna+adyuvada+contra+la+COVID-19+de+Novavax%2C+para+los+profesionales+sanitarios+que+administran+la+vacuna+(proveedores+de+vacunas)+y+la+informaci%C3%B3n+de+prescripci%C3%B3n+completa+de+EUA.)\nAcerca de NVX-CoV2373 (Vacuna adyuvada contra la COVID-19 de Novavax)\nNVX-CoV2373 es una vacuna basada en prote\u00ednas creada a partir de la secuencia gen\u00e9tica de la primera cepa de SARS-CoV-2, el virus que causa la enfermedad COVID-19. La vacuna se cre\u00f3 utilizando la tecnolog\u00eda de nanopart\u00edculas recombinantes de Novavax para generar ant\u00edgenos derivados de la prote\u00edna de espiga (S) del coronavirus y est\u00e1 formulada con el adyuvante Matrix-M\u2122 a base de saponinas, patentado por Novavax, para mejorar la respuesta inmunitaria y estimular altos niveles de anticuerpos neutralizantes. La NVX-CoV2373 contiene ant\u00edgenos de prote\u00edna purificados y no puede replicarse ni causar COVID-19.\nNVX-CoV2373 se presenta como una formulaci\u00f3n l\u00edquida lista para su uso en un vial que contiene diez dosis. El r\u00e9gimen de vacunaci\u00f3n consiste en dos dosis de 0,5 ml (5 mcg de ant\u00edgeno y 50 mcg del adyuvante Matrix-M) administradas por v\u00eda intramuscular con un intervalo de 21 d\u00edas. La vacuna se almacena en un rango de temperatura entre 2 y 8 \u00b0C, lo que permite el uso de los canales de suministro de vacunas y de la cadena de fr\u00edo existentes. El uso de la vacuna est\u00e1 sujeto a las recomendaciones oficiales.\nEl ensayo PREVENT-19 de NVX-CoV2373 se est\u00e1 llevando a cabo con apoyo del gobierno de los Estados Unidos, incluido el Departamento de Defensa, la Autoridad de Investigaci\u00f3n y Desarrollo Avanzado Biom\u00e9dico (BARDA), parte de la Subsecretar\u00eda de Preparaci\u00f3n y Respuesta del HHS y el Instituto Nacional de Alergias y Enfermedades Infecciosas, parte de los Institutos Nacionales de Salud del HHS. BARDA aporta hasta USD 1.750 millones en virtud de un acuerdo con el Departamento de Defensa (# MCDC2011-001). La Oficina Ejecutiva del Programa Conjunto para la Defensa Qu\u00edmica, Biol\u00f3gica, Radiol\u00f3gica y Nuclear del Departamento de Defensa tambi\u00e9n est\u00e1 proporcionando financiaci\u00f3n de hasta 45,7 millones de d\u00f3lares en virtud de un acuerdo separado. Hasta la fecha, el gobierno de los Estados Unidos ha acordado solicitar 3,2 millones de dosis de NVX-CoV2373 en virtud de estos acuerdos existentes en caso de que la NVX-CoV2373 reciba una recomendaci\u00f3n de los CDC. Novavax y el gobierno de los Estados Unidos determinar\u00e1n el momento, el precio y las cantidades para la entrega de cualquier dosis adicional de NVX-CoV2373. Novavax tiene la intenci\u00f3n de concretar otras ventas en los Estados Unidos tanto de dosis de NVX-CoV2373 como de otras formulaciones potenciales.\nNovavax ha establecido asociaciones para la fabricaci\u00f3n, comercializaci\u00f3n y distribuci\u00f3n de NVX-CoV2373 en todo el mundo. Las autorizaciones existentes aprovechan la alianza de fabricaci\u00f3n de Novavax con Serum Institute of India, el fabricante de vacunas m\u00e1s grande del mundo en cuanto a volumen. M\u00e1s adelante, se complementar\u00e1 con datos de otras plantas de fabricaci\u00f3n en la cadena de suministro global de Novavax.\nAcerca del adyuvante Matrix-M\u2122\nEl adyuvante Matrix-M\u2122 basado en saponinas patentado de Novavax ha demostrado un efecto potente y bien tolerado al estimular la entrada de c\u00e9lulas que presentan ant\u00edgenos en el sitio de la inyecci\u00f3n y mejorar la presentaci\u00f3n de ant\u00edgenos en los ganglios linf\u00e1ticos locales, lo que potencia la respuesta inmune.\nAcerca de Novavax\nNovavax, Inc. (Nasdaq:\n[NVAX](#financial-modal)) es una compa\u00f1\u00eda de biotecnolog\u00eda que promueve la mejora de la salud a nivel mundial mediante el descubrimiento, el desarrollo y la comercializaci\u00f3n de vacunas innovadoras para prevenir enfermedades infecciosas graves. La plataforma de tecnolog\u00eda recombinante patentada de la compa\u00f1\u00eda aprovecha el poder y la velocidad de la ingenier\u00eda gen\u00e9tica para producir de manera eficiente nanopart\u00edculas altamente inmunog\u00e9nicas dise\u00f1adas para atender las necesidades urgentes de salud en todo el mundo. NVX-CoV2373, la vacuna contra la COVID-19 de la compa\u00f1\u00eda, ha recibido autorizaci\u00f3n de m\u00faltiples autoridades regulatorias a nivel mundial, incluidos EE. UU., la Comisi\u00f3n Europea y la OMS. En la actualidad, la vacuna est\u00e1 siendo revisada por m\u00faltiples organismos reguladores de todo el mundo, incluso para indicaciones adicionales y poblaciones como adolescentes y como refuerzo. Adem\u00e1s de su vacuna contra la COVID-19, Novavax tambi\u00e9n est\u00e1 evaluando actualmente un candidato a vacuna combinada contra la gripe estacional y la COVID en un ensayo cl\u00ednico de fase 1/2, que combina la NVX-CoV2373 y NanoFlu*, su candidato a vacuna tetravalente contra la gripe en fase de investigaci\u00f3n, y tambi\u00e9n est\u00e1 evaluando una vacuna basada en la cepa \u00f3micron (NVX-CoV2515), as\u00ed como una vacuna bivalente basada en las cepas \u00f3micron y original. Ambas candidatas a vacuna incorporan el adyuvante Matrix-M basado en saponinas patentado de Novavax para mejorar la respuesta inmune y estimular altos niveles de anticuerpos neutralizantes.\nPara obtener m\u00e1s informaci\u00f3n, visite\n[www.novavax.com](https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=2259637382&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D3236043656%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3460980-1%2526h%253D3623927874%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3457869-1%252526h%25253D982408174%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3440781-1%25252526h%2525253D3964594936%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3395501-1%2525252526h%252525253D2463599076%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3392093-1%252525252526h%25252525253D203886192%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3387216-1%25252525252526h%2525252525253D3917401194%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3260461-1%2525252525252526h%252525252525253D2897486098%2525252525252526u%252525252525253Dhttp%25252525252525253A%25252525252525252F%25252525252525252Fwww.novavax.com%25252525252525252F%2525252525252526a%252525252525253Dwww.novavax.com%25252525252526a%2525252525253Dwww.novavax.com%252525252526a%25252525253Dwww.novavax.com%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.novavax.com%2526a%253Dwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com) y con\u00e9ctese con nosotros en\n*NanoFlu identifica una candidata a vacuna contra la influenza por nanopart\u00edculas de prote\u00ednas recombinantes de hemaglutinina (HA) producida por Novavax. Esta candidata en investigaci\u00f3n fue evaluada durante un ensayo controlado de fase 3 realizado durante la temporada de influenza 2019-2020.\nDeclaraciones prospectivas\nLas declaraciones en este documento relativas al futuro de Novavax, sus planes operativos y perspectivas, sus asociaciones, el calendario de los resultados de los ensayos cl\u00ednicos, el desarrollo en curso de NVX-CoV2373, incluida una vacuna basada en la cepa \u00f3micron y una vacuna bivalente basada en la cepa \u00f3micron / original, un candidato a vacuna contra la gripe estacional y la COVID, el alcance, el calendario y el resultado de futuras presentaciones y acciones regulatorias, incluida una posible recomendaci\u00f3n de pol\u00edtica de los Centros para el Control y la Prevenci\u00f3n de Enfermedades, los planes de Novavax para complementar las autorizaciones existentes con datos de los centros de fabricaci\u00f3n adicionales en la cadena de suministro global de Novavax, las autorizaciones mundiales adicionales de NVX-CoV2373 para su uso en adultos y adolescentes, y como refuerzo, el impacto potencial y el alcance de Novavax y NVX-CoV2373 para abordar el acceso a las vacunas, el control de la pandemia y la protecci\u00f3n de las poblaciones, la eficacia, la seguridad y la utilizaci\u00f3n prevista de NVX-CoV2373, y la administraci\u00f3n prevista de NVX-CoV2373 son declaraciones prospectivas. Novavax advierte que estas declaraciones prospectivas est\u00e1n sujetas a numerosos riesgos e incertidumbres que podr\u00edan causar que los resultados reales difieran sustancialmente de los expresados o impl\u00edcitos por dichas declaraciones. Estos riesgos e incertidumbres incluyen, entre otros, desaf\u00edos que satisfacen, por s\u00ed solos o junto con sus socios, varios requerimientos de seguridad, eficacia y caracterizaci\u00f3n de productos, incluidos los que se relacionan con la calificaci\u00f3n del proceso y la validaci\u00f3n del ensayo, necesarios para satisfacer a las autoridades reguladoras correspondientes; demoras o desaf\u00edos imprevistos en la realizaci\u00f3n de los ensayos cl\u00ednicos; dificultades para obtener materias primas y suministros escasos; limitaciones de recursos, incluido el capital humano y la capacidad de fabricaci\u00f3n, para la capacidad de Novavax de seguir v\u00edas regulatorias planificadas; dificultades para cumplir los requerimientos contractuales en virtud de acuerdos con diversas entidades comerciales, gubernamentales y de otros tipos; y los dem\u00e1s factores de riesgo identificados en las secciones \"Risk Factors\" (\"Factores de riesgo\") y \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" (\"An\u00e1lisis y discusi\u00f3n de la gerencia sobre la condici\u00f3n financiera y los resultados de las operaciones\") del informe anual de Novavax en el Formulario 10-K para el a\u00f1o finalizado el 31 de diciembre de 2021 y de los informes trimestrales subsiguientes en el Formulario 10-Q presentados ante la Comisi\u00f3n de Bolsa y Valores (SEC). Advertimos a los inversionistas no depositar un nivel de confianza indebido en las declaraciones prospectivas contenidas en este comunicado de prensa. Le recomendamos leer nuestros archivos registrados ante la SEC, disponibles en\n[www.sec.gov](https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=636516383&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D3403107890%26u%3Dhttps%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&a=www.sec.gov) y [www.novavax.com](https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=4169963879&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D1732560876%26u%3Dhttps%253A%252F%252Fwww.novavax.com%252F%26a%3Dwww.novavax.com&a=www.novavax.com), para analizar estos y otros riesgos e incertidumbres. Las declaraciones prospectivas contenidas en este comunicado de prensa se refieren solamente a la fecha en que este documento fue emitido y no estamos obligados a actualizar ni revisar ninguna de dichas declaraciones. Nuestro negocio est\u00e1 sujeto a riesgos e incertidumbres sustanciales, incluidos aquellos mencionados anteriormente. Los inversionistas actuales y potenciales, y otros interesados deben considerar cuidadosamente estos riesgos e incertidumbres.\nContactos:\nInversionistas\nAlex Delacroix | 240-268-2022\n[[email protected]](/cdn-cgi/l/email-protection#d2bba092bcbda4b3a4b3aafcb1bdbf)\nMedios\nAli Chartan o Giovanna Chandler | 202-709-5563\n[[email protected]](/cdn-cgi/l/email-protection#b0ddd5d4d9d1f0dedfc6d1c6d1c89ed3dfdd)\nLogotipo:\n[https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg](https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=3520536251&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D3696305992%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg)\nFUENTE Novavax, Inc.\nSOURCE Novavax, Inc.", "language": null, "image": "https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg?p=facebook", "pagetype": "articles", "links": ["/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "https://portal.prnewswire.com/Login.aspx", "https://www.prnewswire.com/account/online-membership-form/", "https://gdpr.cision.com/", "https://portal.prnewswire.com/Login.aspx", "/", "/news-releases/", "/products/overview/", "/contact-us/", "#", "/news-releases/", "/news-releases/news-releases-list/", "/news-releases/all-public-company-news/", "/news-releases/english-releases/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/multimedia/multimedia-list/", "/news-releases/photos/photos-list/", "/news-releases/videos/videos-list/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/latest-news-topics/", "#", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/automotive-transportation-latest-news/aerospace-defense-list/", "/news-releases/automotive-transportation-latest-news/air-freight-list/", "/news-releases/automotive-transportation-latest-news/airlines-aviation-list/", "/news-releases/automotive-transportation-latest-news/automotive-list/", "/news-releases/automotive-transportation-latest-news/maritime-shipbuilding-list/", "/news-releases/automotive-transportation-latest-news/railroads-and-intermodal-transportation-list/", "/news-releases/automotive-transportation-latest-news/supply-chain-logistics-list/", "/news-releases/automotive-transportation-latest-news/transportation-trucking-railroad-list/", "/news-releases/automotive-transportation-latest-news/travel-list/", "/news-releases/automotive-transportation-latest-news/trucking-and-road-transportation-list/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/business-technology-latest-news/blockchain-list/", "/news-releases/business-technology-latest-news/broadcast-tech-list/", "/news-releases/business-technology-latest-news/computer-electronics-list/", "/news-releases/business-technology-latest-news/computer-hardware-list/", "/news-releases/business-technology-latest-news/computer-software-list/", "/news-releases/business-technology-latest-news/data-analytics-list/", "/news-releases/business-technology-latest-news/electronic-commerce-list/", "/news-releases/business-technology-latest-news/electronic-components-list/", "/news-releases/business-technology-latest-news/electronic-design-automation-list/", "/news-releases/business-technology-latest-news/financial-technology-list/", "/news-releases/business-technology-latest-news/high-tech-security-list/", "/news-releases/business-technology-latest-news/internet-technology-list/", "/news-releases/business-technology-latest-news/nanotechnology-list/", "/news-releases/business-technology-latest-news/networks-list/", "/news-releases/business-technology-latest-news/peripherals-list/", "/news-releases/business-technology-latest-news/semiconductors-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/financial-services-latest-news/accounting-news-issues-list/", "/news-releases/financial-services-latest-news/acquisitions-mergers-and-takeovers-list/", "/news-releases/financial-services-latest-news/banking-financial-services-list/", "/news-releases/financial-services-latest-news/bankruptcy-list/", "/news-releases/financial-services-latest-news/bond-stock-ratings-list/", "/news-releases/financial-services-latest-news/conference-call-announcements-list/", "/news-releases/financial-services-latest-news/contracts-list/", "/news-releases/financial-services-latest-news/cryptocurrency-list/", "/news-releases/financial-services-latest-news/dividends-list/", "/news-releases/financial-services-latest-news/earnings-list/", "/news-releases/financial-services-latest-news/earnings-forecasts-projections-list/", "/news-releases/financial-services-latest-news/financing-agreements-list/", "/news-releases/financial-services-latest-news/insurance-list/", "/news-releases/financial-services-latest-news/investment-opinions-list/", "/news-releases/financial-services-latest-news/joint-ventures-list/", "/news-releases/financial-services-latest-news/mutual-funds-list/", "/news-releases/financial-services-latest-news/private-placement-list/", "/news-releases/financial-services-latest-news/real-estate-list/", "/news-releases/financial-services-latest-news/restructuring-recapitalization-list/", "/news-releases/financial-services-latest-news/sales-reports-list/", "/news-releases/financial-services-latest-news/shareholder-activism-list/", "/news-releases/financial-services-latest-news/shareholder-meetings-list/", "/news-releases/financial-services-latest-news/stock-offering-list/", "/news-releases/financial-services-latest-news/stock-split-list/", "/news-releases/financial-services-latest-news/venture-capital-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "/news-releases/general-business-latest-news/awards-list/", "/news-releases/general-business-latest-news/commercial-real-estate-list/", "/news-releases/general-business-latest-news/corporate-expansion-list/", "/news-releases/general-business-latest-news/earnings-list/", "/news-releases/general-business-latest-news/environmental-social-governance-list/", "/news-releases/general-business-latest-news/human-resource-workforce-management-list/", "/news-releases/general-business-latest-news/licensing-list/", "/news-releases/general-business-latest-news/new-products-services-list/", "/news-releases/general-business-latest-news/obituaries-list/", "/news-releases/general-business-latest-news/outsourcing-businesses-list/", "/news-releases/general-business-latest-news/overseas-real-estate-list/", "/news-releases/general-business-latest-news/personnel-announcements-list/", "/news-releases/general-business-latest-news/real-estate-transactions-list/", "/news-releases/general-business-latest-news/residential-real-estate-list/", "/news-releases/general-business-latest-news/small-business-services-list/", "/news-releases/general-business-latest-news/socially-responsible-investing-list/", "/news-releases/general-business-latest-news/surveys-polls-and-research-list/", "/news-releases/general-business-latest-news/trade-show-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "#", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/consumer-technology-latest-news/artificial-intelligence-list/", "/news-releases/consumer-technology-latest-news/blockchain-list/", "/news-releases/consumer-technology-latest-news/cloud-computing-internet-of-things-list/", "/news-releases/consumer-technology-latest-news/computer-electronics-list/", "/news-releases/consumer-technology-latest-news/computer-hardware-list/", "/news-releases/consumer-technology-latest-news/computer-software-list/", "/news-releases/consumer-technology-latest-news/consumer-electronics-list/", "/news-releases/consumer-technology-latest-news/cryptocurrency-list/", "/news-releases/consumer-technology-latest-news/data-analytics-list/", "/news-releases/consumer-technology-latest-news/electronic-commerce-list/", "/news-releases/consumer-technology-latest-news/electronic-gaming-list/", "/news-releases/consumer-technology-latest-news/financial-technology-list/", "/news-releases/consumer-technology-latest-news/mobile-entertainment-list/", "/news-releases/consumer-technology-latest-news/multimedia-internet-list/", "/news-releases/consumer-technology-latest-news/peripherals-list/", "/news-releases/consumer-technology-latest-news/social-media-list/", "/news-releases/consumer-technology-latest-news/science-tech-engineering-math-list/", "/news-releases/consumer-technology-latest-news/supply-chain-logistics-list/", "/news-releases/consumer-technology-latest-news/wireless-communications-list/", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/energy-latest-news/alternative-energies-list/", "/news-releases/energy-latest-news/chemical-list/", "/news-releases/energy-latest-news/electrical-utilities-list/", "/news-releases/energy-latest-news/gas-list/", "/news-releases/energy-latest-news/general-manufacturing-list/", "/news-releases/energy-latest-news/mining-list/", "/news-releases/energy-latest-news/mining-metals-list/", "/news-releases/energy-latest-news/oil-energy-list/", "/news-releases/energy-latest-news/oil-and-gas-discoveries-list/", "/news-releases/energy-latest-news/utilities-list/", "/news-releases/energy-latest-news/water-utilities-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/environment-latest-news/conservation-recycling-list/", "/news-releases/environment-latest-news/environmental-issues-list/", "/news-releases/environment-latest-news/environmental-policy-list/", "/news-releases/environment-latest-news/environmental-products-services-list/", "/news-releases/environment-latest-news/green-technology-list/", "/news-releases/environment-latest-news/natural-disasters/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/aerospace-defense-list/", "/news-releases/heavy-industry-manufacturing-latest-news/agriculture-list/", "/news-releases/heavy-industry-manufacturing-latest-news/chemical-list/", "/news-releases/heavy-industry-manufacturing-latest-news/construction-building-list/", "/news-releases/heavy-industry-manufacturing-latest-news/general-manufacturing-list/", "/news-releases/heavy-industry-manufacturing-latest-news/hvac-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machinery-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machine-tools-metalworking-and-metallury-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/paper-forest-products-containers-list/", "/news-releases/heavy-industry-manufacturing-latest-news/precious-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/textiles-list/", "/news-releases/heavy-industry-manufacturing-latest-news/tobacco-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "/news-releases/telecommunications-latest-news/carriers-and-services-list/", "/news-releases/telecommunications-latest-news/mobile-entertainment-list/", "/news-releases/telecommunications-latest-news/networks-list/", "/news-releases/telecommunications-latest-news/peripherals-list/", "/news-releases/telecommunications-latest-news/telecommunications-equipment-list/", "/news-releases/telecommunications-latest-news/telecommunications-industry-list/", "/news-releases/telecommunications-latest-news/voip-list/", "/news-releases/telecommunications-latest-news/wireless-communications-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "#", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/consumer-products-retail-latest-news/animals-pets-list/", "/news-releases/consumer-products-retail-latest-news/beers-wines-and-spirits-list/", "/news-releases/consumer-products-retail-latest-news/beverages-list/", "/news-releases/consumer-products-retail-latest-news/bridal-services-list/", "/news-releases/consumer-products-retail-latest-news/cannabis-list/", "/news-releases/consumer-products-retail-latest-news/cosmetics-and-personal-care-list/", "/news-releases/consumer-products-retail-latest-news/fashion-list/", "/news-releases/consumer-products-retail-latest-news/food-beverages-list/", "/news-releases/consumer-products-retail-latest-news/furniture-and-furnishings-list/", "/news-releases/consumer-products-retail-latest-news/home-improvements-list/", "/news-releases/consumer-products-retail-latest-news/household-consumer-cosmetics-list/", "/news-releases/consumer-products-retail-latest-news/household-products-list/", "/news-releases/consumer-products-retail-latest-news/jewelry-list/", "/news-releases/consumer-products-retail-latest-news/non-alcoholic-beverages-list/", "/news-releases/consumer-products-retail-latest-news/office-products-list/", "/news-releases/consumer-products-retail-latest-news/organic-food-list/", "/news-releases/consumer-products-retail-latest-news/product-recalls-list/", "/news-releases/consumer-products-retail-latest-news/restaurants-list/", "/news-releases/consumer-products-retail-latest-news/retail-list/", "/news-releases/consumer-products-retail-latest-news/supermarkets-list/", "/news-releases/consumer-products-retail-latest-news/toys-list/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/health-latest-news/biometrics-list/", "/news-releases/health-latest-news/biotechnology-list/", "/news-releases/health-latest-news/clinical-trials-medical-discoveries-list/", "/news-releases/health-latest-news/dentistry-list/", "/news-releases/health-latest-news/fda-approval-list/", "/news-releases/health-latest-news/fitness-wellness-list/", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/health-insurance-list/", "/news-releases/health-latest-news/infection-control-list/", "/news-releases/health-latest-news/international-medical-approval-list/", "/news-releases/health-latest-news/medical-equipment-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/mental-health-list/", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/supplementary-medicine-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/sports-latest-news/general-sports-list/", "/news-releases/sports-latest-news/outdoors-camping-hiking-list/", "/news-releases/sports-latest-news/sporting-events-list/", "/news-releases/sports-latest-news/sports-equipment-accessories-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "/news-releases/travel-latest-news/amusement-parks-and-tourist-attractions-list/", "/news-releases/travel-latest-news/gambling-casinos-list/", "/news-releases/travel-latest-news/hotels-and-resorts-list/", "/news-releases/travel-latest-news/leisure-tourism-list/", "/news-releases/travel-latest-news/outdoors-camping-hiking-list/", "/news-releases/travel-latest-news/passenger-aviation-list/", "/news-releases/travel-latest-news/travel-industry-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "#", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "/news-releases/policy-public-interest-latest-news/advocacy-group-opinion-list/", "/news-releases/policy-public-interest-latest-news/animal-welfare-list/", "/news-releases/policy-public-interest-latest-news/congressional-presidential-campaigns-list/", "/news-releases/policy-public-interest-latest-news/corporate-social-responsibility-list/", "/news-releases/policy-public-interest-latest-news/domestic-policy-list/", "/news-releases/policy-public-interest-latest-news/economic-news-trends-analysis-list/", "/news-releases/policy-public-interest-latest-news/education-list/", "/news-releases/policy-public-interest-latest-news/environmental-list/", "/news-releases/policy-public-interest-latest-news/european-government-list/", "/news-releases/policy-public-interest-latest-news/fda-approval-list/", "/news-releases/policy-public-interest-latest-news/federal-and-state-legislation-list/", "/news-releases/policy-public-interest-latest-news/federal-executive-branch-agency-news-list/", "/news-releases/policy-public-interest-latest-news/foreign-policy-international-affairs-list/", "/news-releases/policy-public-interest-latest-news/homeland-security-list/", "/news-releases/policy-public-interest-latest-news/labor-union-news-list/", "/news-releases/policy-public-interest-latest-news/legal-issues-list/", "/news-releases/policy-public-interest-latest-news/natural-disasters-list/", "/news-releases/policy-public-interest-latest-news/not-for-profit-list/", "/news-releases/policy-public-interest-latest-news/patent-law-list/", "/news-releases/policy-public-interest-latest-news/public-safety-list/", "/news-releases/policy-public-interest-latest-news/trade-policy-list/", "/news-releases/policy-public-interest-latest-news/us-state-policy-news-list/", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "#", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/news-releases/multicultural-latest-news/native-american-list/", "/news-releases/multicultural-latest-news/african-american-related-news-list/", "/news-releases/multicultural-latest-news/asian-related-news-list/", "/news-releases/multicultural-latest-news/children-related-news-list/", "/news-releases/multicultural-latest-news/diversity-equity-inclusion/", "/news-releases/multicultural-latest-news/hispanic-oriented-news-list/", "/news-releases/multicultural-latest-news/lesbian-gay-bisexual-list/", "/news-releases/multicultural-latest-news/mens-interest-list/", "/news-releases/multicultural-latest-news/people-with-disabilities-list/", "/news-releases/multicultural-latest-news/religion-list/", "/news-releases/multicultural-latest-news/senior-citizens-list/", "/news-releases/multicultural-latest-news/veterans-list/", "/news-releases/multicultural-latest-news/women-related-news-list/", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/ae/ar/news-releases/", "/comunicados-de-prensa/", "/comunicados-para-a-imprensa/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/de/pressemitteilungen/", "/es/comunicados-de-prensa/", "/fr/communiques-de-presse/", "/it/comunicati-stampa/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/fi/lehdistotiedotteet/", "/sv/pressmeddelanden/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/guaranteed-paid-placement/", "/products/all-products/", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "#nav-mobile", "/", "https://portal.prnewswire.com", "/contact-us/", "javascript:void(0)", "/contact-us/", "/contact-us/", "tel:+1-888-776-0942", "javascript:void(0)", "#", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/business-technology-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/financial-services-latest-news/", "/news-releases/general-business-latest-news/", "/news-releases/consumer-technology-latest-news/", "/news-releases/energy-latest-news/", "/news-releases/environment-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/telecommunications-latest-news/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/health-latest-news/", "/news-releases/sports-latest-news/", "/news-releases/travel-latest-news/", "/news-releases/multicultural-latest-news/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/products/all-products/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/contact-us/#general", "/request-a-demo/", "/contact-us/#editorial", "/contact-us/#partnerships", "/contact-us/#media", "/contact-us/#worldwide", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "#", "/news/novavax%2C-inc./", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", null, "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=2348182560&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D381075886%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-07-11-U-S-Government-Secures-3-2-Million-Doses-of-Novavax-COVID-19-Vaccine%26a%3Dannounced%2Ban%2Bagreement&a=anunci%C3%B3+un+acuerdo", "https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=2890647676&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D1150756867%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2021-12-20-European-Commission-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine%26a%3DEuropean%2BCommission&a=%C2%A0Comisi%C3%B3n+Europea", "https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=2836457404&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D3532952207%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2021-12-20-World-Health-Organization-Grants-Second-Emergency-Use-Listing-for-Novavax-COVID-19-Vaccine%26a%3DWorld%2BHealth%2BOrganization&a=Organizaci%C3%B3n+Mundial+de+la+Salud", "https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=333043435&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D3604531202%26u%3Dhttps%253A%252F%252Fwww.cdc.gov%252Fvaccines%252Fcovid-19%252Fclinical-considerations%252Fmanaging-anaphylaxis.html%26a%3Dthe%2BCenters%2Bfor%2BDisease%2BControl%2B(CDC)%2Band%2BPrevention%2Bguidelines&a=las+directrices+de+los+Centros+para+el+Control+de+Enfermedades+(CDC)+y+su+Prevenci%C3%B3n", "https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=3361234377&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D980972146%26u%3Dhttps%253A%252F%252Fvaers.hhs.gov%252Freportevent.html%26a%3Dhttps%253A%252F%252Fvaers.hhs.gov%252Freportevent.html&a=https%3A%2F%2Fvaers.hhs.gov%2Freportevent.html", "http://www.NovavaxMedInfo.com", "https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=3355049426&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D962771267%26u%3Dhttps%253A%252F%252Fwww.fda.gov%252Fmedia%252F159897%252Fdownload%26a%3DNovavax%2BCOVID-19%2BVaccine%252C%2BAdjuvanted%2BFact%2BSheet%2Bfor%2BHealthcare%2BProviders%2BAdministering%2BVaccine%2B(Vaccine%2BProviders)%2Band%2BEUA%2BFull%2BPrescribing%2BInformation.&a=Hoja+informativa+de+la+vacuna+adyuvada+contra+la+COVID-19+de+Novavax%2C+para+los+profesionales+sanitarios+que+administran+la+vacuna+(proveedores+de+vacunas)+y+la+informaci%C3%B3n+de+prescripci%C3%B3n+completa+de+EUA.", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=2259637382&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D3236043656%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3460980-1%2526h%253D3623927874%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3457869-1%252526h%25253D982408174%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3440781-1%25252526h%2525253D3964594936%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3395501-1%2525252526h%252525253D2463599076%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3392093-1%252525252526h%25252525253D203886192%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3387216-1%25252525252526h%2525252525253D3917401194%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3260461-1%2525252525252526h%252525252525253D2897486098%2525252525252526u%252525252525253Dhttp%25252525252525253A%25252525252525252F%25252525252525252Fwww.novavax.com%25252525252525252F%2525252525252526a%252525252525253Dwww.novavax.com%25252525252526a%2525252525253Dwww.novavax.com%252525252526a%25252525253Dwww.novavax.com%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.novavax.com%2526a%253Dwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com", "https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=775874920&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D3692212473%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3460980-1%2526h%253D91088807%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3457869-1%252526h%25253D1725473980%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3440781-1%25252526h%2525253D2733326919%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3395501-1%2525252526h%252525253D853375093%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3392093-1%252525252526h%25252525253D1325598136%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3387216-1%25252525252526h%2525252525253D2935962557%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3260461-1%2525252525252526h%252525252525253D1508558197%2525252525252526u%252525252525253Dhttps%25252525252525253A%25252525252525252F%25252525252525252Fc212.net%25252525252525252Fc%25252525252525252Flink%25252525252525252F%25252525252525253Ft%25252525252525253D0%252525252525252526l%25252525252525253Den%252525252525252526o%25252525252525253D3158017-1%252525252525252526h%25252525252525253D3702938248%252525252525252526u%25252525252525253Dhttps%2525252525252525253A%2525252525252525252F%2525252525252525252Fwww.linkedin.com%2525252525252525252Fcompany%2525252525252525252Fnovavax%2525252525252525252F%252525252525252526a%25252525252525253DLinkedIn%2525252525252526a%252525252525253DLinkedIn%25252525252526a%2525252525253DLinkedIn%252525252526a%25252525253DLinkedIn%2525252526a%252525253DLinkedIn%25252526a%2525253DLinkedIn%2525&a=LinkedIn", "https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=636516383&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D3403107890%26u%3Dhttps%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&a=www.sec.gov", "https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=4169963879&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D1732560876%26u%3Dhttps%253A%252F%252Fwww.novavax.com%252F%26a%3Dwww.novavax.com&a=www.novavax.com", "/cdn-cgi/l/email-protection#d2bba092bcbda4b3a4b3aafcb1bdbf", "/cdn-cgi/l/email-protection#b0ddd5d4d9d1f0dedfc6d1c6d1c89ed3dfdd", "https://c212.net/c/link/?t=0&l=es&o=3593822-1&h=3520536251&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3593822-1%26h%3D3696305992%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/infection-control-list/", "/news-releases/health-latest-news/biotechnology-list/", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "tel:Cision%20Distribution%20888-776-0942", "javascript://Chat", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "https://twitter.com/PRNewswire", "https://www.facebook.com/PR-Newswire-26247320522/", "https://www.linkedin.com/company/pr-newswire/", "/products/communications-cloud/", "/products/marketing/", "/products/public-relations/", "/products/ir-compliance/", "/products/agency/", "https://www.smallbusinesspr.com/request_information", "/products/all-products/", "https://prnewswire.mediaroom.com/index.php", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "/contact-us/prnewswire-partners/", "/contact-us/become-a-partner/", "https://www.cision.com/careers/", "https://www.cision.com/about/accessibility/", "https://www.prnasia.com/", "https://prnewswire.com.br/", "https://www.newswire.ca/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/fi/lehdistotiedotteet/", "/fr/communiques-de-presse/", "/de/pressemitteilungen/", "/in/news-releases/", "/il/news-releases/", "/it/comunicati-stampa/", "https://prnewswire.com.mx/", "/ae/news-releases/", "https://www.prnewswire.com/ae/ar/news-releases/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/es/comunicados-de-prensa/", "/sv/pressmeddelanden/", "https://www.prnewswire.co.uk/", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "/contact-us", "/products/overview", "https://prnewswire.mediaroom.com/index.php", "", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "tel:Cision%20Distribution%20Helpline", "/terms-of-use/", "/privacy-policy/", "/prn-information-security-policy/", "/sitemap/", "/rss/", "/cookie-settings/", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "javascript://Chat"]}